More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostat

Eur Heart J. 2024 Jan 7;45(2):87-88. doi: 10.1093/eurheartj/ehad756.
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Aldosterone*
  • Antihypertensive Agents / therapeutic use
  • Humans
  • Hypertension* / drug therapy

Substances

  • Aldosterone
  • Antihypertensive Agents